Bioasis Technologies Inc. V.BTI

Last day for tax-loss selling is today!

[prophetoffactz]

1) Last day for tax-loss selling is today.

2) 23 business days until the expiration of the J&J multi-product option for xB3.

3) Midatech's CEO expected NASDAQ trading in the first few days of Feb.

4) Midatech expected to release Q-Sphera tumor data in the early part of the year. No specifics were provided concerning what was meant by early part of the year. Delivering drug directly into a tumor for extended periods of time with Q-Sphera could: a) avoid systemic toxicities that come with many chemo drugs with less frequent dosing; b) probably achieve a higher average dose in the tumor potentially increasing efficacy.

[KayakerBC]

Just more propaganda from a pumper.

[Boomskid]

And Friday Dec 30/22 is the date of record for the AGM/Special Meeting. And if that swell Midatech news bumps its stock 50% it will still be over a penny less than the Bioasis share price is today - CDN $0.038 vs BTI at $0.05 Lawd, Lawd, gimme strength... JD

[prophetoffactz]

With all of those warrants Armistice will have a HUGE incentive to get the stock price up big. Midatech took the stock from $6.50 to $21.50 witihin days on a J&J/Q-Sphera collaboration. What could it do with a multi-product licensing deal on xB3 with J&J, Q-Sphera tumor data, and preclinical xB3 Hunter data as Chiesi potentially gets FDA and European approval for Fabry making it a

[Boomskid]

I think pof is now just trying to annoy everybody. He knows that nobody is interested in reading this stuff he's posting over and over again.   But what can be said, anyway? In my opinion, there is nothing useful coming from the players in this deal. The agreements are so convoluted and the intentions of the players so obscure that Bioasis shareholders have no accurate means of

[craighenry]

"He knows that nobody is interested in reading this stuff he's posting over and over again" And people are interested in what you post nut job?

[Boomskid]

Yes. People, some, a few, many, are interested in what this nut job has to say, Craig. I signed up a week ago. In a few days I will have twice as many thumbs up as you have earned in over 12 years. Please, people, shove some thumbs up his way. Sorry. I have to go get ready. We're expecting your afternoon shriek to begin any moment now. jd

[craighenry]

This post has been removed in accordance with Community Policy

[Boomskid]

Well, I'm not as colourful as you, Craig, nor as bad-tempered. It's more fun being a sick, disturbed, crumbled, lunatic than having to live with anger issues like you do hoo hoo.. But I can pretend to be angry, a regular firebreathing minotaur. Let's get 'er goin'! Gosh. Dang nab it. Holy moly. Howzzat? Wait. I can be more angry than that. What in old dyin' eyed

[craighenry]

Hey JD.... maybe you can buy groceries with "thumbs ups"? You sick pathetic little man..

[Boomskid]

If it's thumb soup you're talking about, Craig, it's a thin soup for your dins tonite. What wuz you going to say about xB3-004? Anything you'd like to talk about? Like, where'd it go? About what I waiting for, I figured that DrDR would get a lousy deal for xB3-001, a lousy deal likely being enough to cash the company up and push the share price up, too, maybe enough to

[craighenry]

This post has been removed in accordance with Community Policy

[Boomskid]

Wow, that's an impressive explosion, Craig! Were there any survivors? JD

[craighenry]

This post has been removed in accordance with Community Policy

[emmitfitzhume]

What would happen to the current deal if one of our partners decided to move forward with one of the assets, ie Janssen, Chiesi, Prothena, Neuramedy, etc.  At the value Bioasis is being given away for in the proposed buyout/takeover, it would seem that any progress on these licensing deals would drastically change the inherent value of Bioasis, and thus would trigger a revaluation of Bioasis,

[narmac]

I would think one would be better off to either buy MTP,,or wait until Biodexa starts trading and gets clobbered!!...Looks like BTI is possibly the least attractive shares based on the end numbers we are presented with.  Its definitely a NO vote on this end.....!! the 1,000,000 shares in our accounts will stand our ground in defiance to this absurdity,,,,,PITIFUL no matter what way you

[Boomskid]

Awful questions, emmitfitzhume. Perfectly appropriate, but awful. My guess is that Bioasis cannot allow any deals to happen - a standstill - to prevent a re-evaluation of the deal. The Bioasis/Janssen deal will expire, I would imagine. If Janssen wants to continue, it will be with Biodexa. After all, this Midatech deal is done like dinner. There will never be a good Bioasis press release

[prophetoffactz]

What if Q-Sphera was used for xB3-Hunter and xB3-Herceptin?

[Boomskid]

pof asked, "What if Q-Sphera was used for xB3-Hunter and xB3-Herceptin?" It makes sense for the delivery of an ERT for an LSD because the LSDs are chronic and steady delivery can eliminate decades of over/under dosing of the ERTs. Q-Spera may have value with brain tumours but Herceptin treatments last only a year and would the added expense of Q-Sphera be worth it?  The value

[fuzzyjr]

Prof's answered many of questions - have you listened to the webinars? Have you ever talked to Graeme? Graeme D. President | Colwell Capital Corp. Tel: [phone] Email:[e-mail] | Web:colwellcapital.com

[Boomskid]

Lol, everybody's talked to Graeme. And then they talk to me. From what I hear, he's only got 5-word cliches for answers about the deal, and nothing about agreement details.  It's not his fault. There's no way that DrDR would give him any substantive talking points.    I don't dispute that there is value to Hunter syndrome. Q-Sphera could also be a

[prophetoffactz]

"But Bioasis, in the Chiesi deal, valued a single LSD at less than $750,000 up front and less than $35 million in milestone payments." Chiesi's Fabry asset was still awaiting hard clinical data and was without FDA/European approvals or filings. Chiesi was not a strategic player in LSDs. It only hoped to be with Fabry as a strategic asset to build around. The xB3/Chiesi deal may

[Boomskid]

Blah, blah, blah, pof. It doesn't make any difference what you say. Bioasis placed their values on the Chiesi LSDs, pure and simple. Is Bioasis now saying that the Chiesi deal was undervalued and that it's all being fixed with one LSD going to Midatech for a fraction of a penny per share? What? Do you think that readers here are that stupid? I'm not saying anything about LSD values

[prophetoffactz]

"Bioasis placed their values on the Chiesi LSDs, pure and simple." With Chiesi soon a strategic player in LSDs given approval for Fabry and xB3 validated to an IND filing, given the first Chiesi deal was worth US138 million will the second LSD deal for the rest and largest LSD opportunities be worth significanlty more than US$1 billion? Denali has also validated delivery to the brain.

[Boomskid]

So, everybody thinks that LSDs have high value. Ok. Then what kind of blithering incompetence did it take to sell 4 of them for $3 million and $34.5 million each? And then to sell, for four cents a share or so, the company that can build dozens of these drugs? It is an astonishing failure. It is an embarrassment of epic magnitude! You can't sell Bioasis and xB3 licenses for pennies, try to

[prophetoffactz]

"Then what kind of blithering incompetence did it take to sell 4 of them for $3 million and $34.5 million each?" That's just your poor analysis. Chiesi's Fabry asset hadn't even completed clinical trials. Chiesi had no strategic importance in terms of LSD and products on the market. Rathjen limited the deal to 4 LSDs because of the risk. Chiesi had to work to prove itself

[Boomskid]

Fabry? pof, the four Chiesi LSDs are secret. You have no proof that one of them is Fabry. It's a good guess, but unless Bioasis told you, you don't know. Further, there is no public evidence that Chiesi is working with Protalix on any of the four LSDs. About clinical trials, PRX-102 completed Phase I/II in 2015 and was in Phase III trials at least 3 years before the Chiesi deal. As